Medicines, shortages, prices, new therapies, warnings, and access to treatment.
According to a study by the Expert Club for Economy and Politics (EKIP), patient costs for medications partially or fully covered by the NHIF exceed 381 million euros for 2025.
Importers of medicines for rare diseases have sent a declaration to the National Assembly and the government, warning that proposed changes to the Medicinal Products Act could halt the supply of critical therapies.
Orthopedist Dr. Hristo Mazneykov revealed the mechanisms leading to higher medicine prices in Bulgaria, such as the difference in the number of tablets per pack and an orientation towards re-export.
The US FDA has approved Lipfendra – the first medication for lowering 'bad' cholesterol that is taken in pill form rather than via injection. This opens a new era in cardiovascular disease therapy.
Patients with rhythm disorders are facing a serious problem due to the lack of medications such as 'Cordarone' and 'Sotagama'. Experts warn of the danger of arbitrarily stopping therapy.
The Ministry of Health proposes new rules for the supply of unapproved and compassionate use medicines. The goal is the digitalization of processes, stricter price control, and cost transparency.
Health economist Arkadi Sharkov warns of huge differences in medicine prices between different healthcare facilities, linking this phenomenon to the new rules for centralized electronic tenders.
We use cookies to run the site, remember your preferences and — only with your consent — for statistics and third-party content. You can change your choice at any time from the footer. Details: Cookie policy